Alkermes has taken another step toward the market with its long-acting version of the schizophrenia drug Abilify, filing for an approval with the FDA as it lays the foundation for a hoped-for launch in 2015.
Alkermes has crossed the finish line in a Phase III schizophrenia study of a long-acting version of Abilify, picking up the statistically significant results needed to back a new drug application later in the year.
It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.
Watchdogs worried about antipsychotic use in children now have more ammo. A new study links the drugs with Type 2 diabetes. Published in the journal JAMA Psychiatry, the study found a threefold increase in diabetes risk for kids who take antipsychotic drugs compared with those taking other psychotropic drugs.
The regulators have spoken on both sides of the Atlantic. And in both cases, we have winners--and we have losers.
A federal judge tossed out a lawsuit filed by health plans unhappy with Bristol-Myers Squibb's co-pay offers on Abilify. The insurers accused the drugmaker of racketeering and bribery for using coupons to combat generic versions of the antipsychotic drug.
Lundbeck has another chance to crow this week, now that its once-monthly version of Abilify has FDA approval. The agency nod comes fast on the heels of another, for the Danish drugmaker's alcohol addiction drug Selincro. This double victory opens the way for Lundbeck to transform turnaround promises into actual sales.
U.S. regulators handed Otsuka Pharmaceutical and Lundbeck some good news today, stamping an approval on the two drugmakers' once-monthly version of the big-selling schizophrenia drug Abilify.
Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...
The market for schizophrenia drugs will shrink over the next couple of years, Decision Resources finds, but will bounce back after that, thanks to new drugs that can be priced at a premium to older treatments.